Triazolone Compounds
Triazolone-based compounds targeting DHODH offer a promising solution for antiviral and autoimmune treatments by effectively inhibiting the DHODH enzyme and demonstrating strong antiviral and anti-inflammatory efficacy.
JP7653456B2Active Publication Date: 2025-03-28シャンハイ ナーウェイ バイオテクノロジー カンパニーリミティド
2 Cites 0 Cited by
Patent Information
- Application Number
- JP2022573319
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-04-02
- Filing Date
- 2021-05-24
- Publication Date
- 2025-03-28
- Estimated Expiration
- 2041-05-24
AI Technical Summary
Technical Problem
Current treatments for antiviral infections and autoimmune diseases, such as rheumatoid arthritis, often face challenges with drug-resistant mutations and side effects, highlighting the need for effective inhibitors targeting DHODH.
Method used
Development of triazolone-based compounds represented by formula (V) and their pharmaceutically acceptable salts, which exhibit strong inhibitory activity against the DHODH enzyme, thereby inhibiting virus replication and reducing inflammatory responses.
Benefits of technology
The triazolone-based compounds demonstrate potent DHODH enzyme inhibition, effective antiviral activity against influenza virus, and significant anti-inflammatory effects, while maintaining excellent pharmacokinetic properties and selectivity.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention discloses a series of triazolone compounds, specifically compounds represented by formula (V) and pharmaceutically acceptable salts thereof: JPEG2023527213000099.jpg48149
Need to check novelty before this filing date? Find Prior Art